Maternal serum biochemical markers PP13, PAPP-A, PlGF and ADAM12 @ 11-13+6 weeks’ gestation and adverse pregnancy outcomes

Abnormal placentation can lead to adverse pregnancy outcomes such as small for gestational age (SGA), pre-eclampsia (PE) and hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, contributing to fetal and maternal morbidity and mortality. In this case control study we aim to investigate first trimester maternal serum PP13, PAPP-A, PlGF and ADAM12 levels in a number of pregnancies which later developed one 9 or more of the following adverse outcomes:PE, IUGR, HELLP and GH.

Rights

Use and reproduction:

No license. The provisions of the German Copyright Act (UrhG) apply.

Please note that individual components of the publication may be subject to other licensing or copyright conditions.

Cite

Citation style:
Could not load citation form.